<<<<<<< HEAD
\BOOKMARK [1][-]{section*.1}{Introduction}{}% 1
\BOOKMARK [1][-]{section*.3}{Results}{}% 2
\BOOKMARK [2][-]{subsection*.4}{Identification of the in vivo WASH complex proteome}{section*.3}% 3
\BOOKMARK [2][-]{subsection*.5}{The SWIPP1019R mutation destabilizes the WASH complex}{section*.3}% 4
\BOOKMARK [2][-]{subsection*.6}{Spatial proteomics analysis of SWIPP1019R mutant mouse brain}{section*.3}% 5
\BOOKMARK [2][-]{subsection*.7}{SWIP mutant neurons display endo-lysosomal structural abnormalities}{section*.3}% 6
\BOOKMARK [2][-]{subsection*.8}{SWIPP1019R mutant brains exhibit lipofuscin accumulation and markers of cell death}{section*.3}% 7
\BOOKMARK [2][-]{subsection*.9}{SWIPP1019R mutant mice display persistent deficits in cued fear memory recall}{section*.3}% 8
\BOOKMARK [2][-]{subsection*.10}{SWIPP1019R mutant mice exhibit surprising motor deficits that are confirmed in human patients}{section*.3}% 9
\BOOKMARK [1][-]{section*.11}{Discussion}{}% 10
\BOOKMARK [1][-]{section*.12}{Acknowledgements}{}% 11
\BOOKMARK [1][-]{section*.13}{Author Contributions}{}% 12
\BOOKMARK [1][-]{section*.14}{Competing Interests}{}% 13
\BOOKMARK [1][-]{section*.15}{Resource Availability}{}% 14
\BOOKMARK [2][-]{subsection*.16}{Lead Contact}{section*.15}% 15
\BOOKMARK [2][-]{subsection*.17}{Materials Availability}{section*.15}% 16
\BOOKMARK [2][-]{subsection*.18}{Data and Code Availability}{section*.15}% 17
\BOOKMARK [1][-]{section*.19}{Materials and Methods}{}% 18
\BOOKMARK [2][-]{subsection*.20}{Animals}{section*.19}% 19
\BOOKMARK [2][-]{subsection*.21}{Human Subjects}{section*.19}% 20
\BOOKMARK [2][-]{subsection*.22}{Cell Lines}{section*.19}% 21
\BOOKMARK [2][-]{subsection*.23}{Primary Neuronal Culture}{section*.19}% 22
\BOOKMARK [2][-]{subsection*.24}{Plasmid DNA Constructs}{section*.19}% 23
\BOOKMARK [2][-]{subsection*.25}{AAV Viral Preparation}{section*.19}% 24
\BOOKMARK [2][-]{subsection*.26}{Immunocytochemistry}{section*.19}% 25
\BOOKMARK [3][-]{subsubsection*.27}{Primary antibodies}{subsection*.26}% 26
\BOOKMARK [3][-]{subsubsection*.28}{Secondary antibodies}{subsection*.26}% 27
\BOOKMARK [2][-]{subsection*.29}{Immunohistochemistry}{section*.19}% 28
\BOOKMARK [3][-]{subsubsection*.30}{Primary antibodies}{subsection*.29}% 29
\BOOKMARK [3][-]{subsubsection*.31}{Secondary antibodies}{subsection*.29}% 30
\BOOKMARK [2][-]{subsection*.32}{Western Blotting}{section*.19}% 31
\BOOKMARK [3][-]{subsubsection*.33}{Primary antibodies}{subsection*.32}% 32
\BOOKMARK [3][-]{subsubsection*.34}{Secondary antibodies}{subsection*.32}% 33
\BOOKMARK [2][-]{subsection*.35}{Immunoprecipitation}{section*.19}% 34
\BOOKMARK [2][-]{subsection*.36}{Electron Microscopy}{section*.19}% 35
\BOOKMARK [2][-]{subsection*.37}{iBioID Sample Preparation}{section*.19}% 36
\BOOKMARK [2][-]{subsection*.38}{LC-MS/MS for iBioID}{section*.19}% 37
\BOOKMARK [2][-]{subsection*.39}{LOPIT-DC Subcellular Fractionation}{section*.19}% 38
\BOOKMARK [2][-]{subsection*.40}{16-plex TMT LC-MS/MS}{section*.19}% 39
\BOOKMARK [2][-]{subsection*.41}{Mouse Behavioral Assays}{section*.19}% 40
\BOOKMARK [3][-]{subsubsection*.42}{Y-maze}{subsection*.41}% 41
\BOOKMARK [3][-]{subsubsection*.43}{Novel Object Recognition}{subsection*.41}% 42
\BOOKMARK [3][-]{subsubsection*.44}{TreadScan}{subsection*.41}% 43
\BOOKMARK [3][-]{subsubsection*.45}{Fear Conditioning}{subsection*.41}% 44
\BOOKMARK [3][-]{subsubsection*.46}{Hearing Test}{subsection*.41}% 45
\BOOKMARK [3][-]{subsubsection*.47}{Somatosensation}{subsection*.41}% 46
\BOOKMARK [1][-]{section*.48}{Quantification and Statistical Analysis}{}% 47
\BOOKMARK [2][-]{subsection*.49}{Imaris 3D reconstruction}{section*.48}% 48
\BOOKMARK [2][-]{subsection*.50}{Cleaved Caspase-3 Image Analysis}{section*.48}% 49
\BOOKMARK [2][-]{subsection*.51}{iBioID Quantitative Analysis}{section*.48}% 50
\BOOKMARK [2][-]{subsection*.52}{TMT Proteomics Quantitative Analysis}{section*.48}% 51
\BOOKMARK [2][-]{subsection*.53}{Module Gene Set Enrichment Analysis}{section*.48}% 52
\BOOKMARK [2][-]{subsection*.54}{Network Visualization}{section*.48}% 53
\BOOKMARK [1][-]{section*.55}{References}{}% 54
\BOOKMARK [1][-]{section*.56}{Funding Sources}{}% 55
=======
>>>>>>> 7d1729a2d0c5adbb9a503db5769f93ed4a301c08
